Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Hypertension. 2016 Aug 1;68(4):949–955. doi: 10.1161/HYPERTENSIONAHA.116.07620

Figure 3.

Figure 3

Effects of human cross-reactive ADAM17 inhibitory antibody, A9B8, on cardiovascular remodeling induced by AngII. A: C57Bl/6 mice were infused with AngII for 2 weeks with treatment of A9B8 or control human IgG2. Tissues were stained with Sirius Red (n=6) or the antibodies indicated (n=4). Representative staining images are presented. B: Heart weight body weight ratio was calculated. Mean±SEM (n=8). C: Mean arterial pressure was evaluated by telemetry (Mean±SEM, n=6). *p<0.05 compared with saline control. †p<0.05 compared with AngII control.